Martin Shkreli is taking aim at Hims & Hers Health (NYSE:HIMS), saying he is short the stock and blasting the company’s peptide products as illegitimate medicine
Shkreli, known as Pharma Bro, posted on X that he is "shorted $HIMS" and calling its peptides "fake medicine," adding that "we have come far in the last 70 years of medicine, let’s not go backwards."
FDA’s Stance on Peptides
Hims & Hers Health’s peptide narrative faces challenges as the FDA recommended against adding seven peptides to the 503A Bulk List. This recommendation, noted by BofA Securities analyst Allen Lutz in a July 1 report, could narrow the legal pathway for peptide compounding.
The FDA’s briefing materials suggest that the Pharmacy Compounding Advisory Committee (PCAC) has a difficult task ahead in attempting to shift the FDA’s stance on these peptides.
